Abstract: AIM: After approval of bevacizumab in Chinese, postmarketing surveillance studies reported on efficacy and safety was rare. We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients in daily practice. METHODS: All unresectable metastatic colorectal cancer patients who began receiving bevacizumab in participating facilities from October 2010 to April 2013 were retrospectively analyzed for efficacy and safety. Response Evaluation in Solid Tumors criteria,version 1.1, was used for the tumor response rate. The Kaplan-Meier method was used to determine PFS and OS. Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: A totalof 74 patients were assessed. Response rates were 62.8%, 28.6% overall among patients re-ceiving bevacizumab as first-,second-line therapy. Median progression-free survival was 8,7,4.4 months,and median overall survival was 25.3, 14.6 months, respectively. All grade adverse events related to bevacizumab included hypertendion in 9.5%, proteinuria in 8.1%, thrombosis in 2.7%,gastrointestinal perforation in 2.7%,poor wound healing in 4.1% and bleeding in 17.6%. CONCLUSION: Although the sample size was small and there were several study limitations, these results suggest that colorectal cancer patients in our center benefit from bevacizumab in combination with chemotherapy and might safely in daily practice.

Key words: colorectal neoplasms, bevacizumab, chemotherapy, efficacy, safety